Product/Composition:- | Glimepiride + Metformin Tablet |
---|---|
Strength:- | Glimepiride 1mg/2mg/3mg/4mg + Metformin 500mg/850mg/1000mg |
Form:- | Tablets |
Reference Brands:- | Amaryl M |
MOQ | As per the manufacturer batch size |
Get Quote Send Enquiry on WhatsApp |
Glimepiride stimulates insulin release from pancreatic β-cells, while Metformin decreases hepatic glucose production and improves insulin sensitivity. Together, they provide complementary actions for better glycemic control in type 2 diabetes. This dual therapy helps reduce fasting and postprandial blood glucose levels, often with fewer side effects than high-dose monotherapy.
Glimepiride + Metformin fixed-dose combination (FDC) tablets are approved in the EU for the management of type 2 diabetes mellitus when monotherapy with either agent is insufficient. EU regulatory bodies support their use based on proven glycemic control efficacy and safety. In the USA, FDCs with Glimepiride are not widely available as branded drugs but may be compounded or prescribed off-label in generic forms. These combinations must meet bioequivalence, labeling, and GMP standards under EMA and FDA guidelines. Pharmatradz.com helps connect buyers with reliable manufacturers offering Glimepiride + Metformin tablets aligned with regional regulatory frameworks.